10-Q: Hypha Labs Reports Q3 2024 Results Following Asset Sale, Shifts Focus

Hypha Labs, formerly Digipath, reports its Q3 2024 results, reflecting the sale of its Digipath Labs subsidiary and a shift in business focus.

Summary

• Hypha Labs, formerly Digipath, released its financial results for the quarter ended June 30, 2024.
• The company completed the sale of its Digipath Labs subsidiary on February 20, 2024, marking a significant shift in its business operations.
• The company reported a net loss of $706,897 from continuing operations for the quarter and a net loss of $904,586 for the nine months ended June 30, 2024.
• The company's cash balance was $509,028 as of June 30, 2024, with negative working capital of $374,215.
• The company's accumulated deficit was $20,081,427 as of June 30, 2024.
• The company issued 4,000,000 shares of common stock for the conversion of $40,000 in principal of convertible note payables.
• The company also issued 21,616,670 shares of common stock for compensation, valued at $536,395.
• The company recognized a gain of $1,502,064 on the sale of Digipath Labs net assets.
• The company's operating loss for the three months ended June 30, 2024 was $613,573, compared to an operating loss of $95,250 for the same period in 2023.
• The company's operating loss for the nine months ended June 30, 2024 was $1,258,184, compared to an operating loss of $356,085 for the same period in 2023.

Sentiment

Score: 3

Explanation: The document indicates a weak financial position with significant losses and negative working capital, despite the gain from the asset sale. The company's ability to continue as a going concern is in doubt, leading to a negative sentiment.

Positives

• The company completed the sale of Digipath Labs, which resulted in a gain of $1,502,064.
• The company received $2,126,934 in cash from the sale of subsidiary assets.
• The company repaid a note payable and related accrued interest in full on February 27, 2024.

Negatives

• The company reported a net loss of $706,897 from continuing operations for the quarter ended June 30, 2024.
• The company has negative working capital of $374,215 as of June 30, 2024.
• The company has an accumulated deficit of $20,081,427 as of June 30, 2024.
• The company's operating loss increased significantly to $613,573 for the three months ended June 30, 2024.
• The company's operating loss increased significantly to $1,258,184 for the nine months ended June 30, 2024.
• The company recorded a loss on debt extinguishment of $956,494.

Risks

• The company has negative working capital and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The company's future success depends on its ability to secure additional capital and identify profitable acquisition targets.
• The company's increased operating losses and expenses pose a risk to its financial stability.
• The company's reliance on stock-based compensation may dilute existing shareholders.

Future Outlook

The company is currently evaluating future investments into potential acquisition targets.

Management Comments

• Management was actively pursuing new customers to increase revenues prior to the agreement to sell the net assets of Digipath Labs.
• Management was seeking additional sources of capital to fund short-term operations.
• Management is currently evaluating future investments into potential acquisition targets.

Industry Context

The company's shift away from cannabis testing reflects a strategic change in response to market conditions and the sale of its Digipath Labs subsidiary. The company is now focused on identifying new business opportunities.

Comparison to Industry Standards

• The company's financial performance is significantly below industry standards for profitability, as evidenced by the substantial operating and net losses.
• The company's negative working capital and accumulated deficit are concerning and indicate a high level of financial distress.
• The company's cash balance of $509,028 is low compared to industry benchmarks for companies of similar size and stage.
• The company's reliance on stock-based compensation is higher than industry averages, which may dilute existing shareholders.
• The company's transition from a service-oriented testing lab to a holding company is a significant departure from its previous business model, making direct comparisons to industry peers difficult.

Related Party Transactions

• The company incurred compensation expense of $95,000 for services provided by its CFO during the nine months ended June 30, 2024.
• The company accrued fees of $15,000 for services provided by its directors during the nine months ended June 30, 2024.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from stock-based compensation.
• Employees may be impacted by the company's restructuring and potential need for cost-cutting measures.
• Creditors face increased risk due to the company's negative working capital and accumulated deficit.
• Customers of the former Digipath Labs are now served by the buyer of those assets.

Next Steps

• The company will evaluate future investments into potential acquisition targets.
• The company will seek additional sources of capital to fund short-term operations.

Key Dates

Keywords

Hypha Labs, Digipath, financial results, asset sale, cannabis testing, net loss, operating loss, convertible notes, stock issuance, going concern